Seminars in Oncology
Volume 35 , Pages S15-S21 , April 2008

Preclinical Investigations With Epothilones in Breast Cancer Models

  • Howard A. Burris III

      Affiliations

    • Corresponding Author InformationAddress correspondence to Howard A. Burris III, MD, FACP, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203

References 

  1. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. Oncologist. 2001;6:133–146
  2. Seidman AD. Systemic treatment of breast cancer (Two decades of progress). Oncology (Williston Park). 2006;20:983–990
  3. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–2333
  4. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem. 1997;272:2534–2541
  5. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist. 2007;12:271–280
  6. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429–1437
  7. Chou TC, O'Connor OA, Tong WP, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci U S A. 2001;98:8113–8118
  8. Zhou Y, Zhong Z, Liu F, et al. KOS-1584: A rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Am Assoc Cancer Res. 2005;46:(abstr 2535) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
  9. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015–2025
  10. Fumoleau P, Coudert B, Isambert N, et al. Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18(suppl 5):v9–v15
  11. Chou TC, Zhang XG, Balog A, et al. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A. 1998;95:9642–9647
  12. Fojo T, Menefee M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol. 2007;18(suppl 5):v3–v8
  13. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures–A new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470:M79–M91
  14. Duran GE, Jordan MA, Sikic BI. Impaired taxane- and epothilone-driven tubulin polymerization in a non-MDR1 taxane-resistant MCF-7 breast cancer variant with reduced MAP4 and elevated MAP Tau content. Proc Am Assoc Cancer Res. 2006;47:(abstr 3755) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
  15. Lee FY, Camuso A, Castenada S, et al. Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types. Proc Am Assoc Cancer Res. 2006;47:(abstr 503) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
  16. Kamath AV, Chang M, Lee FY, et al. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol. 2005;56:145–153
  17. Sessa C, Perotti A, Lladò A, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol. 2007;18:1548–1553
  18. Hoffmann J, Buchmann B, Schwede W, et al. New synthetic epothilone derivative ZK-EPO inhibits breast cancer metastasis. Proc Am Assoc Cancer Res. 2005;46:(abstr 3424) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
  19. Klar U, Buchmann B, Schwede W, et al. ZK-EPO, a novel synthetic epothilone B analog, significantly inhibits tumor growth in both non-resistant and resistant breast cancer models. Breast Cancer Res Treat. 2005;94(suppl 1):S64;(abstr 1072)
  20. Hoffmann J, Winsel S, Hammer S, et al. Activity of the third-generation epothilone ZK-EPO, compared with paclitaxel and other tubulin-binding agents, in the inhibition of breast tumor cell growth and proliferation. Breast Cancer Res Treat. 2006;100(suppl 1):S72;(abstr 1103)
  21. Hoffmann J, Fichtner I, Klar U. ZK-EPO, a potent third-generation epithilone, is effective in models of breast cancer metastasis. Proc Am Assoc Cancer Res. 2006;47:(abstr 511) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
  22. Chou TC, Zhang XG, Harris CR, et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A. 1998;95:15798–15802
  23. Zhong Z, Eng S, Craig D, et al. Tissue distribution and pharmacokinetics (PK) for KOS-1584: A rationally designed microtubule polymerization stabilizer. Proc Am Assoc Cancer Res. 2006;47:(abstr 3098) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)
  24. Chou T-C, Zhang X, Dong H, et al. Therapeutic evaluation of the second-generation epothilone, dehydelone, as a microtubule stabilization antitumor agent in xenograft models. Proc Am Assoc Cancer Res. 2006;47:(abstr 492) Available at: www.aacrmeetingabstracts.org (accessed Nov 7, 2007)

 Dr. Burris has received honoraria from Bristol-Myers Squibb Company, Kosan Biosciences, and Novartis Pharmaceuticals Corporation.

PII: S0093-7754(08)00041-9

doi: 10.1053/j.seminoncol.2008.02.002

Seminars in Oncology
Volume 35 , Pages S15-S21 , April 2008

Article Tools

* Image Usage & Resolution